These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15152631)

  • 21. Fast track to MS drug.
    Sheridan C
    Nat Biotechnol; 2004 Aug; 22(8):939-41. PubMed ID: 15286635
    [No Abstract]   [Full Text] [Related]  

  • 22. New drug approvals for 2002.
    Frantz S; Smith A
    Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538
    [No Abstract]   [Full Text] [Related]  

  • 23. Lymphoma treatment approved.
    AIDS Patient Care STDS; 1998 Mar; 12(3):231. PubMed ID: 11361944
    [No Abstract]   [Full Text] [Related]  

  • 24. Minicrash tests biotechnology investors and companies as market fluctuates.
    Dorey E
    Nat Biotechnol; 1997 Dec; 15(13):1333. PubMed ID: 9415878
    [No Abstract]   [Full Text] [Related]  

  • 25. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
    Dudzinski DM
    Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
    [No Abstract]   [Full Text] [Related]  

  • 26. The therapeutic monoclonal antibody market.
    Ecker DM; Jones SD; Levine HL
    MAbs; 2015; 7(1):9-14. PubMed ID: 25529996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphoma Mabs rivalry continues.
    Webber D
    Nat Biotechnol; 1998 Nov; 16(11):1000-1. PubMed ID: 9831017
    [No Abstract]   [Full Text] [Related]  

  • 28. Biotech blockbusters consolidate markets.
    Lawrence S
    Nat Biotechnol; 2006 Dec; 24(12):1466. PubMed ID: 17160033
    [No Abstract]   [Full Text] [Related]  

  • 29. Why these biotechs are as hot as net stocks. Wall Street's betting big on a genetic technology that burned it badly before. Monoclonal antibodies still don't cure cancer--but this time they may actually pay off.
    McLean B
    Fortune; 2000 Jan; 141(1):132-4, 135. PubMed ID: 10788044
    [No Abstract]   [Full Text] [Related]  

  • 30. MS drug back on market under restricted program.
    FDA Consum; 2006; 40(4):7. PubMed ID: 17243280
    [No Abstract]   [Full Text] [Related]  

  • 31. Monoclonal antibodies: production, uses and side effects.
    Cowden J; Parker SK
    Pediatr Infect Dis J; 2006 Jun; 25(6):553-5. PubMed ID: 16732156
    [No Abstract]   [Full Text] [Related]  

  • 32. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 33. A piece of history.
    Nat Biotechnol; 2003 Aug; 21(8):831. PubMed ID: 12894179
    [No Abstract]   [Full Text] [Related]  

  • 34. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
    Tsuji K; Tsutani K
    Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The challenge of integrating monoclonal antibodies into the current healthcare system.
    Brixner DI; Bull SA
    Am J Manag Care; 1997 Jun; 3(6):903-11. PubMed ID: 10170294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibodies in the clinic.
    Reichert JM
    Nat Biotechnol; 2001 Sep; 19(9):819-22. PubMed ID: 11533635
    [No Abstract]   [Full Text] [Related]  

  • 37. New biotechnology approvals for 2002.
    Piascik P
    J Am Pharm Assoc (Wash); 2003; 43(1):116-7. PubMed ID: 12585761
    [No Abstract]   [Full Text] [Related]  

  • 38. Lymphoma market turf war imminent, pending Bexxar approval.
    Garber K
    Nat Biotechnol; 2003 Feb; 21(2):115-6. PubMed ID: 12560823
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapeutic monoclonal antibodies: trends in development and approval in the US.
    Reichert JM
    Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Researchers see a need for speed in EU trial approvals.
    Cressey D
    Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.